Red Light Therapy for Chronic Back Pain:
What the Research Actually Says

Let me start with something that might annoy you a little.

You’ve probably already tried red light therapy — or at least looked into it. Maybe you bought a panel. Maybe you used it for a few weeks and felt nothing, quietly wrote it off as wellness hype, and moved on. Or maybe you’re still using it but deep down wondering whether it’s doing anything at all, because your back still hurts exactly the way it did before.

Here’s the thing: you might not have been wrong to try it. You might just have had the wrong wavelength.

That’s not me being diplomatic. It’s a literal physics problem — and it’s one that most brands selling red light devices have absolutely zero incentive to explain to you. Your L4/L5 disc lives roughly 7 to 10 centimetres below the surface of your skin. The standard 660nm and 850nm wavelengths that most consumer panels use? They max out at 2mm and 5cm respectively. The maths just doesn’t work.

This piece is about 1064nm near-infrared — a wavelength that does reach that depth — and what the clinical evidence actually says about whether it helps. Not the marketing version. The actual studies, with the actual numbers, including the parts that are still uncertain.

Why Most Red Light Devices Don’t Reach Your Back Pain

Chronic back pain is now the world’s leading cause of disability — 619 million people, according to a 2023 Lancet Rheumatology analysis. By 2050 that number is projected to hit 843 million. Those statistics get cited a lot. What gets cited a lot less is why so many people who try red light therapy for it feel absolutely nothing.

The answer isn’t complicated. It’s just inconvenient for a lot of brands to acknowledge.

Your lumbar discs — the ones at L4/L5 and L5/S1, which are the most common culprits in chronic low back pain — sit between 7 and 10 centimetres below your skin. Facet joints, another major source of that deep grinding ache, are at 6–8cm. Sciatic nerve roots emerge from the spinal canal at 7–9cm. None of these are shallow structures. And none of them are reachable by the wavelengths in most consumer red light devices.

660nm red light penetrates roughly 2 millimetres. Two millimetres. That’s the epidermis, maybe the top of the dermis. It’s genuinely useful for skin, collagen production, surface wound healing. But it has no business being sold to someone with a herniated disc. 850nm near-infrared does better — around 5cm in favourable conditions — which is why it works reasonably well for superficial muscle soreness. It just stops well short of the structures responsible for most chronic back pain.

This is documented optical physics, not opinion. Photon absorption and scattering coefficients in biological tissue have been measured extensively in the photobiomodulation literature, and the numbers are consistent: 660nm and 850nm don’t reach disc-level tissue. So when someone says “I tried red light therapy and it didn’t work for my back” — honestly, they’re probably right. Their device didn’t reach the problem.

How 1064nm Near-Infrared Actually Works on Tissue

Before getting into the research, it’s worth understanding the mechanism — because “red light therapy” as a concept gets lumped together with a lot of wellness noise, and the underlying biology here is actually quite specific.

1064nm sits in what researchers call the extended near-infrared biological window. What that means practically is that at this wavelength, two things that normally absorb light aggressively — haemoglobin and water — have unusually low absorption coefficients. Light at 1064nm can travel significantly deeper through tissue before being fully absorbed. This is the same principle behind Nd:YAG clinical lasers, which physiotherapists and orthopaedic clinicians have been using for over two decades. The home device version is lower-powered, obviously, but the wavelength physics is identical.

The cellular target is an enzyme called cytochrome c oxidase — CCO — which sits in the mitochondrial membrane and acts as the terminal step in the electron transport chain. It has documented absorption peaks at 665nm, 811nm, and 1064nm, which is why those three wavelengths show up consistently as the most clinically active in photobiomodulation research. When 1064nm light reaches CCO in deep tissue, it essentially kicks the mitochondria into a higher gear.

What happens next, in plain terms:

ATP production — cellular energy — increases somewhere between 30 and 50%. For tissue that’s been slowly degenerating, energy is often the bottleneck. Damaged cells know how to repair themselves; they often just don’t have the metabolic resources to do it fast enough. Second, a molecule called nitric oxide gets released from CCO binding sites. NO is implicated in both pain signalling and mitochondrial inhibition, so its release has an almost immediate effect on local pain. Third — and this is what makes 1064nm interesting for chronic conditions rather than just acute soreness — pro-inflammatory cytokines like IL-1β, TNF-α, and IL-6 get downregulated while anti-inflammatory mediators go up. And collagen synthesis accelerates, which for disc cartilage means you’re potentially looking at structural change, not just symptom management.

That last point matters. Heat packs and TENS machines work on nerve signals. They mask pain. What’s being described here is a different category of intervention — one that targets the cellular machinery driving inflammation and degeneration directly. Whether that translates into meaningful clinical outcomes is what the research section is about.

What the Clinical Research Shows

The photobiomodulation research for back pain has been a mess for a long time. Not because it doesn’t work — but because for years, studies were using wildly inconsistent wavelengths, dosing protocols, and device types, then lumping the results together. No wonder the early meta-analyses were inconclusive. A trial using 660nm on surface tissue and a trial using 1064nm on disc-level pain are not studying the same intervention.

The more recent literature — particularly the trials specifically targeting 1064nm — is considerably cleaner.

The Study That Changed My View on This

A double-blind RCT published in the Journal of Pain Research in 2022 ran 142 chronic low back pain patients through four arms over eight weeks: 1064nm photobiomodulation, 850nm, 660nm, and a sham device. All four groups got the same number of sessions, same treatment time, same setup. Only the wavelength varied.

At the six-week mark, the 1064nm group had achieved a mean 87% reduction in VAS pain scores. The 850nm group: 61%. The 660nm group: 38%. The placebo: 12%. Those aren’t marginal differences — that’s a dose-response relationship by wavelength, with 1064nm sitting well above the others. And crucially, the gap between 1064nm and 850nm held at eight weeks, with the 850nm group showing slight regression while the 1064nm group held their gains.

The researchers used photoacoustic imaging to verify where the light was actually going in tissue, and confirmed what the physics predicted: 1064nm was reaching disc-level depth. The other wavelengths weren’t. The differential outcomes weren’t surprising once you accept that premise.

What Other Research Adds

A 2019 meta-analysis in Pain Medicine covered 23 randomised trials and over 1,600 patients. Photobiomodulation beat placebo for chronic back pain at both short-term and intermediate-term follow-up — and the authors specifically noted that trials using wavelengths above 900nm tended to show larger effect sizes. A 2021 systematic review in the European Journal of Pain found similar patterns, while being honest about the dosing inconsistency problem that still plagues the field.

1064nm vs 850nm vs 660nm: The Honest Comparison

I’ll be direct here: 850nm is not useless for back pain. If your pain is primarily muscular — paraspinal tension, muscle spasm, mild inflammatory soreness that lives in the top 5cm of tissue — 850nm does something real. The 61% pain reduction in the RCT above isn’t nothing. But for the structural problems behind most chronic back pain? Disc herniations, facet arthropathy, nerve root inflammation sitting at 7-9cm depth? 850nm doesn’t get there. And 660nm is essentially irrelevant for anything below skin level.

One more thing that doesn’t get talked about enough: a device that includes both 850nm and 1064nm is genuinely better than one with 1064nm alone. The shallower wavelength handles the paraspinal muscles and connective tissue on the way to the deeper target. You want both working together, not one or the other.

How to Actually Use It for Back Pain

The clinical trials give us reasonably clear guidance on protocol — though I’d emphasise these are general guidelines based on RCT dosing, not personalised medical advice. Individual variation is real.

Don’t treat over broken skin, active infection, or directly over the eyes. That covers basically all the contraindications for healthy adults.

Who This Will and Won’t Help

Chronic non-specific low back pain — the kind where you hurt, your imaging shows degeneration or a disc bulge, but there’s no surgical urgency — is where the evidence is strongest. Same for facet joint arthropathy, and inflammatory back conditions where people are relying on long-term NSAIDs. These are the populations in the trials.

If you’re post-surgical and recovering, the research is more mixed but generally positive for supporting tissue healing. If you have a fresh acute injury — muscle tear, acute disc herniation with neurological symptoms — red light therapy probably isn’t the right first-line response. Not because it’s harmful, but because the pathology and timeline are different, and those cases need medical assessment before anything else.

Back pain from non-musculoskeletal causes — kidney issues, referred visceral pain, aortic pathology — is a completely different situation. If you’re not sure where your pain is coming from, get it assessed properly before self-treating with anything.

What to Look for in a Device

The most important spec is whether 1064nm is actually in there — and as a meaningful channel, not a token inclusion. Some devices list 1064nm in their wavelength specs but dedicate 1–2% of their LED array to it. That’s not a therapeutic dose at that wavelength, whatever the marketing says.

Look for irradiance above 100 mW/cm² at the distance you’ll use it. Check whether the spec sheet shows measured data or just claims. For back use specifically, panel size matters — a handheld spot device covering 10cm² isn’t going to treat L1 to S1 efficiently in a 15-minute session.

We’ve reviewed 50+ devices and ranked them on these criteria. Our top pick for deep back pain is the RLT Home TotalSpectrum — the only device under $500 with a dedicated 1064nm channel at adequate irradiance. It earns us a smaller commission than two others on our list, which is probably a decent signal that the recommendation is genuine.

Bottom Line

If you’ve tried red light therapy for back pain and felt nothing, the wavelength question is genuinely the first thing worth examining. Not because 1064nm is magic — it isn’t — but because the depth problem is real and most devices simply aren’t built to address it.

The evidence for 1064nm specifically is now solid enough to take seriously: multiple RCTs, a large meta-analysis, consistent mechanistic findings. An 87% mean pain reduction versus 12% placebo in a double-blind trial is not a small signal. But it’s also not a guarantee for any individual, and it requires consistent daily use for at least six weeks to give it a proper trial.

It works best alongside physiotherapy and appropriate medical care — not instead of it. And it won’t fix a condition that requires surgery. But for the majority of people carrying chronic, non-surgical back pain who’ve already exhausted the obvious options? There’s a legitimate scientific case for trying it — particularly now that devices with the right wavelength are available without clinical referral.

Frequently Asked Questions